SciCross has experience in the design of both therapeutic cancer vaccines and vaccines against infectious disease. In the case of cancer vaccines, the starting point is a set of tumor-specific (TSA) or tumour-associated (TAA) antigens. However, in a personalised vaccine setting, the starting material can also be sequence information from a single patient. In the case of infectious disease, the information is typically sequenced pathogenic genomes.
SciCross in silico T-cell epitope prediction algorithms can be used to identify both HLA class I and HLA class II epitopes within the antigens. Population aspects and other important information concerning developability are also taken into account in the computational procedure in order to achieve an optimal vaccine candidate.